Sage Therapeutics (SAGE) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.

11 brokers have issued 1-year price targets for Sage Therapeutics' shares. Their SAGE share price forecasts range from $40.00 to $70.00. On average, they anticipate the company's share price to reach $51.54 in the next twelve months. This suggests that the stock has a possible downside of 13.4%.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.

Sage Therapeutics' stock was trading at $38.14 at the beginning of the year. Since then, SAGE stock has increased by 56.1% and is now trading at $59.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our SAGE earnings forecast.

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, May, 2nd. The biopharmaceutical company reported ($2.46) EPS for the quarter, topping analysts' consensus estimates of ($2.50) by $0.04. The biopharmaceutical company earned $3.30 million during the quarter, compared to analysts' expectations of $2.28 million. Sage Therapeutics had a negative net margin of 5,932.09% and a negative trailing twelve-month return on equity of 42.32%. The company's revenue for the quarter was up 120.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.07) earnings per share.

ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Simplify Propel Opportunities ETF (SURI), Subversive Mental Health ETF (SANE), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.85%), Wellington Management Group LLP (9.56%), BlackRock Inc. (8.25%), State Street Corp (4.58%), Price T Rowe Associates Inc. MD (3.19%) and Dimensional Fund Advisors LP (2.77%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends.

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $59.54.

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $3.56 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($9.37) on an earnings per share basis.

The company employs 471 workers across the globe.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.